MedTrace Logo

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

NCT00354003 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2019-04-03

No results posted yet for this study

Summary

The overall goal of the study is to evaluate how research participants in Parkinson Disease studies that include brain imaging with a dopamine transporter ligand choose to receive the imaging data and what is the impact of the imaging data information on the management of their symptoms.

Conditions

  • Parkinsonian Syndrome
  • Parkinson

Interventions

BEHAVIORAL

A series of questionnaires

Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Kenneth Marek, MD · Institute for Neurodegenerative Disorders

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-06-27
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354003 on ClinicalTrials.gov